知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

26 条记录 (耗时 0.021 秒)

    Preparation of substituted hydroxypyrazoles
    2.
    发明申请
    Preparation of substituted hydroxypyrazoles 失效
    取代羟基吡唑的制备

    公开(公告)号：US20030109717A1

    公开(公告)日：2003-06-12

    申请号：US10228373

    申请日：2002-08-27

    发明人： Norbert Gotz ,  Roland Gotz ,  Michael Rack

    IPC分类号： C07D231/14

    CPC分类号： C07C243/30 ,  C07D231/20

    摘要： A process for preparing compounds of the formula I 1 in which R1 is hydrogen, an aliphatic group having 1-8 carbon atoms, C1-C6-alkoxycarbonyl, C1-C6-alkylthiocarbonyl or a cyclic ring system having 3-14 ring atoms, and R2 is hydrogen, an aliphatic group having 1-8 carbon atoms, or R1 and R2 together with the carbon atom to which they are bound form a cyclic or bicyclic ring system having 3-14 ring atoms, comprises the preparation of compounds of the formula II 2 in which R3 and R4 are readily detachable groups and R1 and R2 are as defined above, as starting materials or intermediates and the cyclization of these under suitable reaction conditions to give compounds of the formula I. The intermediates of the formula II are novel.

    摘要翻译： 制备其中R 1为氢，具有1-8个碳原子的脂族基团，C 1 -C 6烷氧基羰基，C 1 -C 6烷基硫代羰基或具有3-14个环原子的环状体系的式I化合物的方法，以及R2 是氢，具有1-8个碳原子的脂族基团，或者R1和R2与它们所连接的碳原子一起形成具有3-14个环原子的环状或双环体系，包括制备式II化合物 其中R 3和R 4是易脱离的基团，并且R 1和R 2如上定义，作为原料或中间体，并在合适的反应条件下环化，得到式Ⅰ化合物。式Ⅱ的中间体是新的。

    COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE
    10.
    发明申请
    COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE 审中-公开

    公开(公告)号：US20190023660A1

    公开(公告)日：2019-01-24

    申请号：US15755729

    申请日：2016-09-02

    申请人： CELLIXBIO PRIVATE LIMITED

    发明人： Mahesh KANDULA

    IPC分类号： C07D221/18 ,  C07C243/30 ,  C07C233/49 ,  A61P25/16 ,  A61P9/12

    CPC分类号： C07D221/18 ,  A61P9/12 ,  A61P25/16 ,  C07C233/49 ,  C07C243/30

    摘要： The invention relates to the compounds of formula I, formula II and formula III or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II and formula III, and methods for treating or preventing Parkinson's disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment or management of Parkinson's disease such as Parkinson's disease, scleroderma, restless leg syndrome, hypertension and gestational hypertension.